Ramipril for the Treatment of Oligospermia

• Status: Terminated
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: Male

Summary

This is a randomized controlled trial to evaluate the effect of ramipril in stimulating and promoting sperm production in men with low sperm count. Ramipril is an Angiotensin Converting Enzyme Inhibitor (ACEI) currently used to treat high blood pressure. However, previous studies have shown that this class of medications can improve sperm parameters. The purpose of this study is to evaluate the efficacy of ramipril compared to placebo (Substance That is not known to have treatment effect), in improving sperm density in infertile men with documented low sperm count. This study will help us identify subjects that might benefit from treatment with this medication, and the effect it will have on sperm count, shape, and motility.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Weill Medical College of Cornell University
• Treatments: Ramipril

Criteria

Inclusion Criteria:

1. Male partner of a couple presenting for infertility.

2. Moderate abnormalities of semen parameters (Mean sperm density <20 million, but ≥ 3 million/ml), and/or motility < 50%, and/or < 4% abnormal morphology on at least two separate occasions.

3. Age 18-45 years.

4. Normal renal function defined as Glomerular filtration rate > 90

Exclusion Criteria:

1. Patients that are currently taking thiazide, cyclosporin, lithium, and allopurinol or the use of these medications in the last 2 weeks.

2. The frequent use of NSAIDS (3 or more times a week).

3. Vasectomy reversal.

4. Regular use of tobacco products.

5. Mean white blood cell count >1 million/ml in the ejaculate.

6. Inability or unwillingness to participate in evaluations required by the study.

7. Potassium > 5.0.

8. Systolic blood pressure < 90 mmHg.

9. Currently use of ACEI